BiotechTube
Stem Genomics

Stem Genomics

Montpellier, France· Est.
stemgenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Stem Genomics is a specialized service provider addressing critical quality control needs in the stem cell research and cell therapy sectors. The company's core value proposition is a 'one-stop-shop' offering of standardized, ISSCR-compliant assays that help researchers and developers ensure the genomic stability, identity, and sterility of their cell lines. Leveraging expertise from its academic founders and proprietary technologies like the iCS-digital™ PSC assay, Stem Genomics serves a global client base of over 150 organizations, positioning itself as a key enabler for advancing safe and credible stem cell-based applications. Its operational footprint includes headquarters in Montpellier, France, and a commercial presence in Research Triangle Park, North Carolina, USA.

Genetics & GenomicsDiagnostics

Technology Platform

Suite of molecular assays for stem cell characterization, including proprietary digital PCR-based iCS-digital™ PSC for genomic stability, STR profiling for authentication, pluripotency/differentiation assays, mycoplasma detection, and NGS services.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The growing stem cell research and cell therapy market, driven by increased R&D funding and regulatory mandates for rigorous cell characterization, presents a significant expansion opportunity.
Establishing a US office allows direct access to the world's largest biopharma market.
Evolving from a research service provider to a GMP-compliant testing partner for cell therapy manufacturing represents a potential long-term, high-value growth path.

Risk Factors

The company's success is highly dependent on the continued growth and funding of the stem cell sector, which faces scientific and regulatory hurdles.
Competition from large CROs and the potential commoditization of some assays could pressure margins and market share.
Rapid technological change in genomics requires continuous R&D investment to keep services relevant.

Competitive Landscape

Stem Genomics competes in a niche segment against generic molecular biology CROs (e.g., Eurofins, Charles River Labs' discovery services), academic core facilities, and other specialized stem cell service providers. Its key differentiators are its exclusive focus on stem cells, deep cell-type-specific expertise, ISSCR standards alignment, and proprietary assays like iCS-digital™ PSC. The competitive threat is the ability of larger players to bundle services or compete on price for more standardized tests.

More companies in Cell & Gene Therapy →More companies in France →